Neurogene Inc (NGNE)
40.33
+1.15
(+2.94%)
USD |
NASDAQ |
Sep 27, 16:00
40.32
-0.01
(-0.02%)
After-Hours: 20:00
Neurogene Cash from Investing (Quarterly): -23.61M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -23.61M |
March 31, 2024 | 29.94M |
December 31, 2023 | 25.83M |
Date | Value |
---|---|
September 30, 2023 | -0.082M |
June 30, 2023 | -0.082M |
March 31, 2023 | -0.029M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-23.61M
Minimum
Jun 2024
29.94M
Maximum
Mar 2024
5.326M
Average
-0.0555M
Median
Cash from Investing (Quarterly) Benchmarks
CEL-SCI Corp | -0.0235M |
AIM ImmunoTech Inc | 0.826M |
IGC Pharma Inc | -0.131M |
NovaBay Pharmaceuticals Inc | -0.002M |
Protalix BioTherapeutics Inc | -0.18M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -15.89M |
Cash from Financing (Quarterly) | 0.399M |
Free Cash Flow | -66.82M |
Free Cash Flow Per Share (Quarterly) | -0.9653 |
Free Cash Flow Yield | -18.01% |